Shuyen Ho
Research Subjects
Shuyen Ho has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ding-Geng Chen
College of Health Solutions Arizona State University Phoenix Arizona USA
5 shared publications - Joseph Christopher Cappelleri
Pfizer Inc. New York New York USA
4 shared publications - Naitee Ting
Boehringer Ingelheim Pharmaceuticals, Inc
4 shared publications - C. Gerald Crawford
GSK, Global Medical, Stockley Park, Uxbridge, Middlesex, UK
1 shared publication Charlotte Baidoo
GSK, Clinical Statistics, Stockley Park, Uxbridge, Middlesex, UK
1 shared publication- Courtney Crim
GlaxoSmithKline, Respiratory, Research Triangle Park, North Carolina, United States
1 shared publication
Latest Publications
- Open Access
- 1 March 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 615-629
Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
Background: Batefenterol is a novel bifunctional muscarinic antagonist β2-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose–response of batefenterol and select a dose for Phase III development. Patients and methods: Patients aged ≥40 years with COPD and FEV1 ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300, or 600 µg, placebo, or umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg once daily. The primary and secondary endpoints were weighted-mean FEV1 over 0–6 hours post-dose and trough FEV1, analyzed by Bayesian and maximum likelihood estimation Emax of dose–response modeling, respectively, on day 42. Results: In the intent-to-treat population (N=323), all batefenterol doses demonstrated statistically and clinically significant improvements from baseline vs placebo in the primary and secondary endpoints (191.1–292.8 and 182.2–244.8 mL, respectively), with a relatively flat dose–response. In the subgroup reversible to salbutamol, there were greater differences between batefenterol doses. Lung function improvements with batefenterol ≥150 µg were comparable with those with UMEC/VI. Batefenterol was well tolerated and no new safety signals were observed. Conclusion: Batefenterol 300 µg may represent the optimal dose for Phase III studies.
- 1 March 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 615-629
Open AccessRandomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
Background: Batefenterol is a novel bifunctional muscarinic antagonist β2-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose–response of batefenterol and select a dose for Phase III development. Patients and methods: Patients aged ≥40 years with COPD and FEV1 ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300, or 600 µg, placebo, or umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg once daily. The primary and secondary endpoints were weighted-mean FEV1 over 0–6 hours post-dose and trough FEV1, analyzed by Bayesian and maximum likelihood estimation Emax of dose–response modeling, respectively, on day 42. Results: In the intent-to-treat population (N=323), all batefenterol doses demonstrated statistically and clinically significant improvements from baseline vs placebo in the primary and secondary endpoints (191.1–292.8 and 182.2–244.8 mL, respectively), with a relatively flat dose–response. In the subgroup reversible to salbutamol, there were greater differences between batefenterol doses. Lung function improvements with batefenterol ≥150 µg were comparable with those with UMEC/VI. Batefenterol was well tolerated and no new safety signals were observed. Conclusion: Batefenterol 300 µg may represent the optimal dose for Phase III studies.
- 3 July 2018
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 10 (3) , 166-175
Data-Driven Prior Distributions for A Bayesian Phase-2 COPD Dose-Finding Clinical Trial
The prior distribution reflects knowledge and uncertainty of the modeled parameters. Determining the prior distribution for a dose-finding clinical trial can be influential in its design and analysis. Using the planning of a phase 2 trial for COPD with a dose-response curve as a case study, we illustrate the use of relevant historical data for the nonlinear curve mean-model parameters as well as consideration for terms to characterize between-trial and within-trial variability. Through a predictive inference exercise, a data-driven informative prior distribution is constructed for the future study. We share our strategies on how to obtain informative Bayesian priors for both design and analysis of dose-finding clinical trials using relevant historical data and deal with the associated issues.
- 3 July 2018
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 10 (3) , 166-175
Data-Driven Prior Distributions for A Bayesian Phase-2 COPD Dose-Finding Clinical Trial
The prior distribution reflects knowledge and uncertainty of the modeled parameters. Determining the prior distribution for a dose-finding clinical trial can be influential in its design and analysis. Using the planning of a phase 2 trial for COPD with a dose-response curve as a case study, we illustrate the use of relevant historical data for the nonlinear curve mean-model parameters as well as consideration for terms to characterize between-trial and within-trial variability. Through a predictive inference exercise, a data-driven informative prior distribution is constructed for the future study. We share our strategies on how to obtain informative Bayesian priors for both design and analysis of dose-finding clinical trials using relevant historical data and deal with the associated issues.
- 16 May 2017
- Published by Taylor & Francis in Communications in Statistics - Simulation and Computation
- Vol. 46 (10) , 7957-7971
From statistical power to statistical assurance: It's time for a paradigm change in clinical trial design
A well-designed clinical trial requires an appropriate sample size with adequate statistical power to address trial objectives. The statistical power is traditionally defined as the probability of rejecting the null hypothesis with a pre-specified true clinical treatment effect. This power is a conditional probability conditioned on the true but actually unknown effect. In practice, however, this true effect is never a fixed value. Thus, we discuss a newly proposed alternative to this conventional statistical power: statistical assurance, defined as the unconditional probability of rejecting the null hypothesis. This kind of assurance can then be obtained as an expected power where the expectation is based on the prior probability distribution of the unknown treatment effect, which leads to the Bayesian paradigm. In this article, we outline the transition from conventional statistical power to the newly developed assurance and discuss the computations of assurance using Monte Carlo simulation-based approach.
- 16 May 2017
- Published by Taylor & Francis in Communications in Statistics - Simulation and Computation
- Vol. 46 (10) , 7957-7971
From statistical power to statistical assurance: It's time for a paradigm change in clinical trial design
A well-designed clinical trial requires an appropriate sample size with adequate statistical power to address trial objectives. The statistical power is traditionally defined as the probability of rejecting the null hypothesis with a pre-specified true clinical treatment effect. This power is a conditional probability conditioned on the true but actually unknown effect. In practice, however, this true effect is never a fixed value. Thus, we discuss a newly proposed alternative to this conventional statistical power: statistical assurance, defined as the unconditional probability of rejecting the null hypothesis. This kind of assurance can then be obtained as an expected power where the expectation is based on the prior probability distribution of the unknown treatment effect, which leads to the Bayesian paradigm. In this article, we outline the transition from conventional statistical power to the newly developed assurance and discuss the computations of assurance using Monte Carlo simulation-based approach.
- 13 April 2017
- Published by Springer Nature
- p. 131-143
Risks of Inconclusiveness
- 13 April 2017
- Published by Springer Nature
- p. 93-115
Design of Dose-Ranging Trials
- 13 April 2017
- Published by Springer Nature
- p. 27-53
Concept of Alpha
- 13 April 2017
- Published by Springer Nature
- p. 225-241
Overview of Phase III Clinical Trials